Breckenridge Pharmaceutical announced the launch of Everolimus Tablets 1mg, a generic version of Novartis' Zortress, marking the completion of their full strength portfolio for this critical immunosuppressant medication. The product became available on October 30, 2025, developed in collaboration with Natco Pharma Limited, India.
Complete Portfolio Now Available
The 1mg strength represents the final piece in Breckenridge's everolimus portfolio, joining previously launched strengths of 0.25mg, 0.5mg, and 0.75mg. The company initially launched blister card configurations in July 2021, followed by bottle presentations in June 2023.
"We are excited to now offer all strengths of Everolimus Tablets in both bottles and blister card configurations," stated Brian Guy, President and CCO of Breckenridge Pharmaceutical. "We continue to focus on the development of therapies that provide affordable access to all patients and address unmet medical needs."
Clinical Application and Mechanism
Everolimus functions as an mTOR inhibitor immunosuppressant, specifically indicated for the prophylaxis of organ rejection in adult patients undergoing kidney and liver transplantation. The medication will be distributed predominantly through retail pharmacies, mail order services, and clinical settings.
Market Access Strategy
As a subsidiary of Towa International based in Barcelona, Spain, Breckenridge Pharmaceutical focuses on bringing cost-effective generic pharmaceuticals to U.S. patients. The company partners with manufacturers globally to ensure reliable supply and quality manufacturing while maintaining competitive pricing for essential medications.
The launch of this final strength provides transplant patients and healthcare providers with comprehensive dosing options for everolimus therapy, potentially improving medication adherence and clinical outcomes through more precise dosing flexibility.
